Analysts Set Expectations for Cytokinetics FY2026 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Cytokinetics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould anticipates that the biopharmaceutical company will earn ($3.59) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share.

Other equities analysts also recently issued research reports about the stock. Morgan Stanley set a $67.00 price target on shares of Cytokinetics in a research note on Friday, March 7th. Citigroup dropped their price objective on Cytokinetics from $86.00 to $80.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. UBS Group reduced their target price on Cytokinetics from $47.00 to $41.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. JMP Securities reissued a "market outperform" rating and set a $78.00 price target on shares of Cytokinetics in a research report on Thursday, April 10th. Finally, Royal Bank of Canada dropped their price target on Cytokinetics from $82.00 to $80.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Three investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $70.92.

Cytokinetics Trading Up 3.6%

Shares of CYTK traded up $1.18 during mid-day trading on Tuesday, hitting $34.38. The company had a trading volume of 1,604,354 shares, compared to its average volume of 1,555,349. Cytokinetics has a 1-year low of $29.31 and a 1-year high of $61.38. The business's 50-day simple moving average is $34.83 and its 200-day simple moving average is $42.39. The stock has a market cap of $4.11 billion, a PE ratio of -6.39 and a beta of 0.59. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.05. The business had revenue of $1.60 million during the quarter, compared to analysts' expectations of $2.77 million. During the same quarter last year, the firm earned ($1.33) EPS. The firm's quarterly revenue was up 89.1% compared to the same quarter last year.

Insiders Place Their Bets

In other Cytokinetics news, EVP Andrew Callos sold 8,659 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $32.04, for a total value of $277,434.36. Following the completion of the sale, the executive vice president now owns 52,028 shares of the company's stock, valued at $1,666,977.12. This trade represents a 14.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert I. Blum sold 12,648 shares of Cytokinetics stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.38, for a total transaction of $561,318.24. Following the sale, the chief executive officer now owns 326,533 shares in the company, valued at $14,491,534.54. This represents a 3.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,700 shares of company stock worth $3,514,393 over the last quarter. 2.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Fifth Third Bancorp boosted its stake in shares of Cytokinetics by 42.2% during the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 291 shares during the last quarter. State of Michigan Retirement System boosted its stake in Cytokinetics by 1.1% during the 1st quarter. State of Michigan Retirement System now owns 28,200 shares of the biopharmaceutical company's stock valued at $1,133,000 after purchasing an additional 300 shares during the period. Louisiana State Employees Retirement System grew its holdings in Cytokinetics by 0.9% in the 1st quarter. Louisiana State Employees Retirement System now owns 33,100 shares of the biopharmaceutical company's stock worth $1,330,000 after buying an additional 300 shares in the last quarter. State of Alaska Department of Revenue grew its stake in shares of Cytokinetics by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 13,820 shares of the biopharmaceutical company's stock worth $555,000 after purchasing an additional 365 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 374 shares in the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.